Lantheus Medical Imaging Declares Supporting FDA's Warning Updates for MRI Contrast Agents

As the U.S. Food and Drug Administration (FDA) has recently announced warning labels updates requirements for three of the currently used MRI gadolinium-based contrast agents, Lantheus Medical Imaging, Inc., has declared its full support for this decision.